Muhammad Rashid
University of Leicester1 paperOpenAlex
Papers
Diabetes, Obesity & MetabolismHumans
GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
In patients with chronic kidney disease, adding a GLP-1 receptor agonist was associated with fewer major adverse kidney events (HR 0.70) than SGLT2…In patients with chronic kidney disease, adding a GLP-1 receptor agonist was associated with fewer major adverse kidney events (HR 0.70) than SGLT2 inhibitors alone.